Tislelizumab Plus Chemotherapy Demonstrates Four-Year Survival Benefit in Advanced Squamous Lung Cancer
Four-year follow-up data from the phase 3 RATIONALE-307 trial demonstrate sustained overall and progression-free survival improvements with first-line tislelizumab plus ...








